{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:10:29Z","timestamp":1790172629621,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T00:00:00Z","timestamp":1539388800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11940-018-0537-y","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T21:02:46Z","timestamp":1539378166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Current Treatment Strategies and Future Treatment Options for Dravet Syndrome"],"prefix":"10.1007","volume":"20","author":[{"given":"Julie","family":"Ziobro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Eschbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly G.","family":"Knupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,13]]},"reference":[{"key":"537_CR1","doi-asserted-by":"publisher","first-page":"e1310","DOI":"10.1542\/peds.2015-1807","volume":"136","author":"YW Wu","year":"2015","unstructured":"Wu YW, Sullivan J, McDaniel SS, Meisler MH, Walsh EM, Li SX, et al. Incidence of Dravet syndrome in a US population. Pediatrics. 2015;136:e1310\u20135. \n                      https:\/\/doi.org\/10.1542\/peds.2015-1807\n                      \n                    .","journal-title":"Pediatrics"},{"key":"537_CR2","doi-asserted-by":"publisher","first-page":"18-34.e3","DOI":"10.1016\/j.pediatrneurol.2017.01.025","volume":"68","author":"Elaine C. Wirrell","year":"2017","unstructured":"\u2022\u2022 Wirrell EC, Laux L, Donner E, Jette N, Knupp K, Meskis MA, et al. Optimizing the diagnosis and management of dravet syndrome: recommendations from a north american consensus panel. Pediatr. Neurol. 2017. \n                      https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.01.025\n                      \n                     This provides updated consensus recommendations on diagnosis, management of seizures, and management of comorbidities.","journal-title":"Pediatric Neurology"},{"key":"537_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.clinph.2016.11.021","volume":"128","author":"N Verbeek","year":"2017","unstructured":"Verbeek N, Kasteleijn-Nolst Trenit\u00e9 D, Wassenaar M, van Campen J, Sonsma A, Gunning WB, et al. Photosensitivity in Dravet syndrome is under-recognized and related to prognosis. Clin Neurophysiol. 2017;128:323\u201330. \n                      https:\/\/doi.org\/10.1016\/j.clinph.2016.11.021\n                      \n                    .","journal-title":"Clin Neurophysiol"},{"key":"537_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0883073811419262","volume":"27","author":"N Specchio","year":"2012","unstructured":"Specchio N, Balestri M, Trivisano M, Japaridze N, Striano P, Carotenuto a, et al. Electroencephalographic features in Dravet syndrome: five-year follow-up study in 22 patients. J Child Neurol. 2012;27:439\u201344. \n                      https:\/\/doi.org\/10.1177\/0883073811419262\n                      \n                    .","journal-title":"J Child Neurol"},{"key":"537_CR5","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1093\/brain\/aws151","volume":"135","author":"A Brunklaus","year":"2012","unstructured":"Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135:2329\u201336. \n                      https:\/\/doi.org\/10.1093\/brain\/aws151\n                      \n                    .","journal-title":"Brain"},{"key":"537_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eplepsyres.2016.10.006","volume":"128","author":"Monica S. Cooper","year":"2016","unstructured":"\u2022 Cooper MS, Mcintosh A, Crompton DE, McMahon JM, Schneider A, Farrell K, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016. \n                      https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.10.006\n                      \n                     This is a recent update in mortality in the Dravet population.","journal-title":"Epilepsy Research"},{"key":"537_CR7","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/epi.12303","volume":"54","author":"EC Wirrell","year":"2013","unstructured":"Wirrell EC, Laux L, Franz DN, Sullivan J, Saneto RP, Morse RP, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013;54:1595\u2013604. \n                      https:\/\/doi.org\/10.1111\/epi.12303\n                      \n                    .","journal-title":"Epilepsia"},{"key":"537_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eplepsyres.2016.05.012","volume":"125","author":"Paola De Liso","year":"2016","unstructured":"De Liso, P., Chemaly, N., Laschet, J., Barnerias, C., Hully, M., Leunen, D., Desguerre, I., Chiron, C., Dulac, O., Nabbout, R.: Patients with dravet syndrome in the era of stiripentol: a French cohort cross-sectional study. Epilepsy Res (2016). doi:\n                      https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.05.012\n                      \n                    , 125, 42, 46.","journal-title":"Epilepsy Research"},{"issue":"9242","key":"537_CR9","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"\u2022 Chiron C, Marchand MC, Tran A, Rey E, D\u2019Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet. 2000. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(00)03157-3\n                      \n                     Trial demonstrating efficacy of stiripentol.","journal-title":"The Lancet"},{"key":"537_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eplepsyres.2014.10.014","volume":"109","author":"A Dressler","year":"2015","unstructured":"Dressler A, Trimmel-Schwahofer P, Reithofer E, M\u00fchlebner A, Gr\u00f6ppel G, Reiter-Fink E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81\u20139. \n                      https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.10.014\n                      \n                    .","journal-title":"Epilepsy Res"},{"key":"537_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/01.wnl.0000265222.24102.db","volume":"69","author":"P Striano","year":"2007","unstructured":"Striano P, Coppola A, Pezzella M, Ciampa C, Specchio N, Ragona F, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;69:250\u20134. \n                      https:\/\/doi.org\/10.1212\/01.wnl.0000265222.24102.db\n                      \n                    .","journal-title":"Neurology"},{"key":"537_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1528-1157.1998.tb01413.x","volume":"39","author":"R Guerrini","year":"1998","unstructured":"Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39:508\u201312. \n                      https:\/\/doi.org\/10.1111\/j.1528-1157.1998.tb01413.x\n                      \n                    .","journal-title":"Epilepsia"},{"key":"537_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/1750-1172-8-176","volume":"8","author":"R Nabbout","year":"2013","unstructured":"Nabbout R, Chemaly N, Chipaux M, Barcia G, Bouis C, Dubouch C, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013;8:176. \n                      https:\/\/doi.org\/10.1186\/1750-1172-8-176\n                      \n                    .","journal-title":"Orphanet J Rare Dis"},{"key":"537_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/dmcn.12593","volume":"57","author":"L Dalic","year":"2015","unstructured":"Dalic L, Mullen SA, Roulet Perez E, Scheffer I. Lamotrigine can be beneficial in patients with Dravet syndrome. Dev Med Child Neurol. 2015;57:200\u20132. \n                      https:\/\/doi.org\/10.1111\/dmcn.12593\n                      \n                    .","journal-title":"Dev Med Child Neurol"},{"key":"537_CR15","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/epi.14191","volume":"59","author":"IM Lange de","year":"2018","unstructured":"de Lange IM, Gunning B, Sonsma ACM, van Gemert L, van Kempen M, Verbeek NE, et al. Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A -related seizure phenotypes. Epilepsia. 2018;59:1154\u201365. \n                      https:\/\/doi.org\/10.1111\/epi.14191\n                      \n                    .","journal-title":"Epilepsia"},{"key":"537_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/jcpt.12659","volume":"43","author":"M Morimoto","year":"2017","unstructured":"Morimoto M, Shimakawa S, Hashimoto T, Kitaoka T, Kyotani S. Marked efficacy of combined three-drug therapy (sodium valproate, topiramate and stiripentol) in a patient with Dravet syndrome. J Clin Pharm Ther. 2017;43:571\u20133. \n                      https:\/\/doi.org\/10.1111\/jcpt.12659\n                      \n                    .","journal-title":"J Clin Pharm Ther"},{"key":"537_CR17","unstructured":"Katz, R.: Approval package for application number: 203993Orig1s000 (Onfi), \n                      https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203993Orig1s000Approv.pdf"},{"key":"537_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40262-014-0223-5","volume":"54","author":"V Jullien","year":"2015","unstructured":"Jullien V, Chhun S, Rey E, Dulac O, Tod M, Chiron C, et al. Pharmacokinetics of clobazam and N-desmethylclobazam in children with Dravet syndrome receiving concomitant stiripentol and valproic acid. Clin Pharmacokinet. 2015;54:527\u201336. \n                      https:\/\/doi.org\/10.1007\/s40262-014-0223-5\n                      \n                    .","journal-title":"Clin Pharmacokinet"},{"key":"537_CR19","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","volume":"58","author":"TE Gaston","year":"2017","unstructured":"Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586\u201392. \n                      https:\/\/doi.org\/10.1111\/epi.13852\n                      \n                    .","journal-title":"Epilepsia"},{"key":"537_CR20","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40262-017-0592-7","volume":"57","author":"S Peign\u00e9","year":"2018","unstructured":"Peign\u00e9 S, Chhun S, Tod M, Rey E, Rodrigues C, Chiron C, et al. Population pharmacokinetics of stiripentol in paediatric patients with Dravet syndrome treated with stiripentol, valproate and clobazam combination therapy. Clin Pharmacokinet. 2018;57:739\u201348. \n                      https:\/\/doi.org\/10.1007\/s40262-017-0592-7\n                      \n                    .","journal-title":"Clin Pharmacokinet"},{"key":"537_CR21","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/dmcn.13704","volume":"60","author":"KA Myers","year":"2018","unstructured":"Myers KA, Lightfoot P, Patil SG, Cross JH, Scheffer IE. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study. Dev Med Child Neurol. 2018;60:574\u20138. \n                      https:\/\/doi.org\/10.1111\/dmcn.13704\n                      \n                    .","journal-title":"Dev Med Child Neurol"},{"key":"537_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40263-018-0511-y","volume":"32","author":"KG Knupp","year":"2018","unstructured":"Knupp KG, Wirrell EC. Treatment strategies for Dravet syndrome. CNS Drugs. 2018;32:335\u201350. \n                      https:\/\/doi.org\/10.1007\/s40263-018-0511-y\n                      \n                    .","journal-title":"CNS Drugs"},{"key":"537_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0920-1211(02)00010-4","volume":"49","author":"G Coppola","year":"2002","unstructured":"Coppola G, Capovilla G, Montagnini A, Romeo A, Span\u00f2 M, Tortorella G, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002;49:45\u20138. \n                      https:\/\/doi.org\/10.1016\/S0920-1211(02)00010-4\n                      \n                    .","journal-title":"Epilepsy Res"},{"key":"537_CR24","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1053\/seiz.2000.0466","volume":"9","author":"M Nieto-Barrera","year":"2000","unstructured":"Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, Ruiz del Portal L. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9:590\u20134. \n                      https:\/\/doi.org\/10.1053\/seiz.2000.0466\n                      \n                    .","journal-title":"Seizure"},{"key":"537_CR25","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1111\/j.1528-1167.2011.03107.x","volume":"52","author":"R Nabbout","year":"2011","unstructured":"Nabbout R, Copioli C, Chipaux M, Chemaly N, Desguerre I, Dulac O, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011;52:e54\u20137. \n                      https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03107.x\n                      \n                    .","journal-title":"Epilepsia"},{"key":"537_CR26","doi-asserted-by":"publisher","first-page":"e00973","DOI":"10.1002\/brb3.973","volume":"8","author":"Q Wu","year":"2018","unstructured":"Wu Q, Wang H, Fan YY, Zhang JM, Liu XY, Fang XY, et al. Ketogenic diet effects on 52 children with pharmacoresistant epileptic encephalopathy: a clinical prospective study. Brain Behav. 2018;8:e00973. \n                      https:\/\/doi.org\/10.1002\/brb3.973\n                      \n                    .","journal-title":"Brain Behav"},{"key":"537_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.seizure.2010.12.017","volume":"20","author":"S Chhun","year":"2011","unstructured":"Chhun S, Troude P, Villeneuve N, Soufflet C, Napuri S, Motte J, et al. A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: continuous spikes and waves during sleep is definitely a target. Seizure. 2011;20:320\u20135. \n                      https:\/\/doi.org\/10.1016\/j.seizure.2010.12.017\n                      \n                    .","journal-title":"Seizure"},{"key":"537_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5692\/clinicalneurol.55.151","volume":"55","author":"S Inoue","year":"2015","unstructured":"Inoue S, Yazawa S, Murahara T, Yamauchi R, Shimohama S. Dramatic seizure reduction with levetiracetam in adult Dravet syndrome: a case report. Rinsho Shinkeigaku. 2015;55:151\u20134. \n                      https:\/\/doi.org\/10.5692\/clinicalneurol.55.151\n                      \n                    .","journal-title":"Rinsho Shinkeigaku"},{"key":"537_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.seizure.2017.06.007","volume":"50","author":"M Dibu\u00e9-Adjei","year":"2017","unstructured":"Dibu\u00e9-Adjei M, Fischer I, Steiger H-J, Kamp MA. Efficacy of adjunctive vagus nerve stimulation in patients with Dravet syndrome: a meta-analysis of 68 patients. Seizure. 2017;50:147\u201352. \n                      https:\/\/doi.org\/10.1016\/j.seizure.2017.06.007\n                      \n                    .","journal-title":"Seizure"},{"key":"537_CR30","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00381-016-3201-4","volume":"32","author":"BJ Dlouhy","year":"2016","unstructured":"Dlouhy BJ, Miller B, Jeong A, Bertrand ME, Limbrick DD, Smyth MD. Palliative epilepsy surgery in Dravet syndrome\u2014case series and review of the literature. Childs Nerv Syst. 2016;32:1703\u20138. \n                      https:\/\/doi.org\/10.1007\/s00381-016-3201-4\n                      \n                    .","journal-title":"Childs Nerv Syst"},{"issue":"21","key":"537_CR31","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"Orrin Devinsky","year":"2017","unstructured":"\u2022 Devinsky O, Cross J, Laux L, Marsh E, Miller I, Nabbout R, et al. Cannabidiol in Dravet syndrome study group: trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011\u201320. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1611618\n                      \n                     Trial demonstrating efficacy of cannabidiol in children with Dravet syndrome.","journal-title":"New England Journal of Medicine"},{"key":"537_CR32","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204\u201311. \n                      https:\/\/doi.org\/10.1212\/WNL.0000000000005254\n                      \n                    .","journal-title":"Neurology"},{"key":"537_CR33","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMc1708349","volume":"377","author":"R Tang","year":"2017","unstructured":"Tang R, Fang F. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;377:699\u2013700. \n                      https:\/\/doi.org\/10.1056\/NEJMc1708349\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"537_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.yebeh.2018.01.026","volume":"80","author":"GS Porcari","year":"2018","unstructured":"Porcari GS, Fu C, Doll ED, Carter EG, Carson RP. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: practical experiences in a tertiary medical center. Epilepsy Behav. 2018;80:240\u20136. \n                      https:\/\/doi.org\/10.1016\/j.yebeh.2018.01.026\n                      \n                    .","journal-title":"Epilepsy Behav"},{"key":"537_CR35","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085\u201396. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(18)30136-3\n                      \n                    .","journal-title":"Lancet"},{"key":"537_CR36","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of Cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome. N Engl J Med. 2018;378:1888\u201397. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1714631\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"537_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.eplepsyres.2009.02.014","volume":"85","author":"P Iannetti","year":"2009","unstructured":"Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res. 2009;85:89\u201395. \n                      https:\/\/doi.org\/10.1016\/j.eplepsyres.2009.02.014\n                      \n                    .","journal-title":"Epilepsy Res"},{"key":"537_CR38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.seizure.2013.09.009","volume":"23","author":"F Nicita","year":"2014","unstructured":"Nicita F, Spalice A, Papetti L, Nikanorova M, Iannetti P, Parisi P. Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study. Seizure. 2014;23:36\u201340. \n                      https:\/\/doi.org\/10.1016\/j.seizure.2013.09.009\n                      \n                    .","journal-title":"Seizure"},{"key":"537_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.yebeh.2015.05.008","volume":"47","author":"Nienke E. Verbeek","year":"2015","unstructured":"Verbeek, N.E., Wassenaar, M., van Campen, J.S., Sonsma, A., Gunning, B., Knoers, N., Lindhout, D., Jansen, F.E., Leijten, F., Brilstra, E.H., Kasteleijn-Nolst Trenit\u00e9, D.: Seizure precipitants in Dravet syndrome: what events and activities are specifically provocative compared with other epilepsies? Epilepsy Behav (2015). doi:\n                      https:\/\/doi.org\/10.1016\/j.yebeh.2015.05.008\n                      \n                    , 47, 39, 44.","journal-title":"Epilepsy & Behavior"},{"key":"537_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/mgg3.217","volume":"4","author":"T Dj\u00e9mi\u00e9","year":"2016","unstructured":"Dj\u00e9mi\u00e9 T, Weckhuysen S, von Spiczak S, Carvill GL, Jaehn J, Anttonen A-K, et al. Pitfalls in genetic testing: the story of missed SCN1A mutations. Mol Genet Genomic Med. 2016;4:457\u201364. \n                      https:\/\/doi.org\/10.1002\/mgg3.217\n                      \n                    .","journal-title":"Mol Genet Genomic Med"},{"key":"537_CR41","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1212\/WNL.0000000000000521","volume":"82","author":"A Fasano","year":"2014","unstructured":"Fasano A, Borlot F, Lang AE, Andrade DM. Antecollis and levodopa-responsive parkinsonism are late features of dravet syndrome. Neurology. 2014;82:2250\u20131. \n                      https:\/\/doi.org\/10.1212\/WNL.0000000000000521\n                      \n                    .","journal-title":"Neurology"},{"key":"537_CR42","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1111\/j.1528-1167.2011.03129.x","volume":"52","author":"A Brunklaus","year":"2011","unstructured":"Brunklaus A, Dorris L, Zuberi SM. Comorbidities and predictors of health-related quality of life in Dravet syndrome. Epilepsia. 2011;52:1476\u201382. \n                      https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03129.x\n                      \n                    .","journal-title":"Epilepsia"},{"key":"537_CR43","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/epi.12652","volume":"55","author":"A Brunklaus","year":"2014","unstructured":"Brunklaus A, Zuberi SM. Dravet syndrome - from epileptic encephalopathy to channelopathy. Epilepsia. 2014;55:979\u201384. \n                      https:\/\/doi.org\/10.1111\/epi.12652\n                      \n                    .","journal-title":"Epilepsia"},{"key":"537_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2017.06.008","volume":"76","author":"KG Knupp","year":"2017","unstructured":"Knupp KG, Scarbro S, Wilkening G, Juarez-Colunga E, Kempe A, Dempsey A. Parental perception of comorbidities in children with Dravet syndrome. Pediatr Neurol. 2017;76:60\u20135. \n                      https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.06.008\n                      \n                    .","journal-title":"Pediatr Neurol"},{"key":"537_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.eplepsyres.2015.11.020","volume":"120","author":"Domenica Battaglia","year":"2016","unstructured":"Battaglia, D., Ricci, D., Chieffo, D., Guzzetta, F.: Outlining a core neuropsychological phenotype for Dravet syndrome. Epilepsy Res. Feb, 91\u201397 (2016). doi:\n                      https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.11.020\n                      \n                    , 120.","journal-title":"Epilepsy Research"},{"key":"537_CR46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.yebeh.2015.10.027","volume":"54","author":"D Chieffo","year":"2016","unstructured":"Chieffo D, Battaglia D, Lucibello S, Gambardella ML, Moriconi F, Ferrantini G, et al. Disorders of early language development in Dravet syndrome. Epilepsy Behav. 2016;54:30\u20133. \n                      https:\/\/doi.org\/10.1016\/j.yebeh.2015.10.027\n                      \n                    .","journal-title":"Epilepsy Behav"},{"key":"537_CR47","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/j.1528-1167.2012.03583.x","volume":"53","author":"JJ Rilstone","year":"2012","unstructured":"Rilstone JJ, Coelho FM, Minassian BA, Andrade DM. Dravet syndrome: seizure control and gait in adults with different SCN1A mutations. Epilepsia. 2012;53:1421\u20138. \n                      https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03583.x\n                      \n                    .","journal-title":"Epilepsia"},{"key":"537_CR48","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1001\/archneurol.2011.3275","volume":"69","author":"JM Rodda","year":"2012","unstructured":"Rodda JM, Scheffer IE, McMahon JM, Berkovic SF, Graham HK. Progressive gait deterioration in adolescents with Dravet syndrome. Arch Neurol. 2012;69:873\u20138. \n                      https:\/\/doi.org\/10.1001\/archneurol.2011.3275\n                      \n                    .","journal-title":"Arch Neurol"},{"key":"537_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/dmcn.13601","volume":"60","author":"SH Licheni","year":"2018","unstructured":"Licheni SH, Mcmahon JM, Schneider AL, Davey MJ, Scheffer IE. Sleep problems in Dravet syndrome: a modifiable comorbidity. Dev Med Child Neurol. 2018;60:192\u20138. \n                      https:\/\/doi.org\/10.1111\/dmcn.13601\n                      \n                    .","journal-title":"Dev Med Child Neurol"},{"key":"537_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.seizure.2017.09.021","volume":"52","author":"K Eschbach","year":"2017","unstructured":"Eschbach K, Scarbro S, Juarez-Colunga E, Allen V, Hsu S, Knupp K. Growth and endocrine function in children with Dravet syndrome. Seizure. 2017;52:117\u201322. \n                      https:\/\/doi.org\/10.1016\/j.seizure.2017.09.021\n                      \n                    .","journal-title":"Seizure"},{"key":"537_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40272-016-0171-7","volume":"18","author":"A Wallace","year":"2016","unstructured":"Wallace A, Wirrell E, Kenney-Jung DL. Pharmacotherapy for Dravet syndrome. Pediatr Drugs. 2016;18:197\u2013208. \n                      https:\/\/doi.org\/10.1007\/s40272-016-0171-7\n                      \n                    .","journal-title":"Pediatr Drugs"},{"key":"537_CR52","doi-asserted-by":"publisher","first-page":"7111","DOI":"10.1523\/JNEUROSCI.5193-09.2010","volume":"30","author":"PJ Schoonheim","year":"2010","unstructured":"Schoonheim PJ, Arrenberg AB, Del Bene F, Baier H. Optogenetic localization and genetic perturbation of saccade-generating neurons in zebrafish. J Neurosci. 2010;30:7111\u201320. \n                      https:\/\/doi.org\/10.1523\/JNEUROSCI.5193-09.2010\n                      \n                    .","journal-title":"J Neurosci"},{"key":"537_CR53","doi-asserted-by":"publisher","unstructured":"Griffin A, Hamling KR, Knupp K, Hong SG, Lee LP, Baraban SC. Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain. 2017:aww342. \n                      https:\/\/doi.org\/10.1093\/brain\/aww342\n                      \n                    .","DOI":"10.1093\/brain\/aww342"},{"key":"537_CR54","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/ncomms3410","volume":"4","author":"SC Baraban","year":"2013","unstructured":"Baraban SC, Dinday MT, Hortopan GA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun. 2013;4:2410. \n                      https:\/\/doi.org\/10.1038\/ncomms3410\n                      \n                    .","journal-title":"Nat Commun"},{"key":"537_CR55","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.2174\/1381612823666170809100524","volume":"23","author":"G Zaccara","year":"2018","unstructured":"Zaccara G, Schmidt D. Antiepileptic drugs in clinical development: differentiate or die? Curr Pharm Des. 2018;23:5593\u2013605. \n                      https:\/\/doi.org\/10.2174\/1381612823666170809100524\n                      \n                    .","journal-title":"Curr Pharm Des"},{"key":"537_CR56","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1080\/03007995.2017.1355781","volume":"33","author":"A-S Schoonjans","year":"2017","unstructured":"Schoonjans A-S, Marchau F, Paelinck BP, Lagae L, Gammaitoni A, Pringsheim M, et al. Current medical research and opinion cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Curr Med Res Opin. 2017;33:1773\u201381. \n                      https:\/\/doi.org\/10.1080\/03007995.2017.1355781\n                      \n                    .","journal-title":"Curr Med Res Opin"},{"key":"537_CR57","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","volume":"53","author":"B Ceulemans","year":"2012","unstructured":"Ceulemans B, Boel M, Leyssens K, Van Rossem C, Neels P, Jorens PG, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53:1131\u20139. \n                      https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03495.x\n                      \n                    .","journal-title":"Epilepsia"},{"key":"537_CR58","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1111\/epi.13407","volume":"57","author":"B Ceulemans","year":"2016","unstructured":"Ceulemans B, Schoonjans AS, Marchau F, Paelinck BP, Lagae L. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57:e129\u201334. \n                      https:\/\/doi.org\/10.1111\/epi.13407\n                      \n                    .","journal-title":"Epilepsia"},{"key":"537_CR59","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581\u20138. \n                      https:\/\/doi.org\/10.1056\/NEJM199708283370901\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"537_CR60","doi-asserted-by":"publisher","unstructured":"Dahl CF, Allen MR, Urie PM, Hopkins PN. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med. 2008;6. \n                      https:\/\/doi.org\/10.1186\/1741-7015-6-34\n                      \n                    .","DOI":"10.1186\/1741-7015-6-34"},{"issue":"6","key":"537_CR61","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/1756285615607726","volume":"8","author":"An-Sofie Schoonjans","year":"2015","unstructured":"Schoonjans, A.S., Lagae, L., Ceulemans, B.: Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome, (2015).","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"537_CR62","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1017\/cjn.2016.249","volume":"43","author":"EC Wirrell","year":"2016","unstructured":"Wirrell EC. Treatment of Dravet syndrome. Can J Neurol Sci\/J Can des Sci Neurol. 2016;43:S13\u20138. \n                      https:\/\/doi.org\/10.1017\/cjn.2016.249\n                      \n                    .","journal-title":"Can J Neurol Sci\/J Can des Sci Neurol"},{"key":"537_CR63","volume-title":"ZX008 (Fenfluramine) in Dravet syndrome: results of a phase 3","author":"L Lagae","year":"2017","unstructured":"Lagae L, Sullivan JE, Cross JH, Devinsky O, Guerrini R, Knupp KG, et al. ZX008 (Fenfluramine) in Dravet syndrome: results of a phase 3. Double-Blind, Placebo-Controlled Trial, AESnet.org: Randomized; 2017."},{"key":"537_CR64","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/cns.12285","volume":"20","author":"G Orban","year":"2014","unstructured":"Orban G, Bombardi C, Marino Gammazza A, Colangeli R, Pierucci M, Pomara C, et al. Role(s) of the 5-HT2C receptor in the development of maximal dentate activation in the hippocampus of anesthetized rats. CNS Neurosci Ther. 2014;20:651\u201361. \n                      https:\/\/doi.org\/10.1111\/cns.12285\n                      \n                    .","journal-title":"CNS Neurosci Ther"},{"key":"537_CR65","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1568026053386980","volume":"5","author":"M Isaac","year":"2005","unstructured":"Isaac M. Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs. Curr Top Med Chem. 2005;5:59\u201367. \n                      https:\/\/doi.org\/10.2174\/1568026053386980\n                      \n                    .","journal-title":"Curr Top Med Chem"},{"key":"537_CR66","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.neuropharm.2016.04.016","volume":"108","author":"M Venzi","year":"2016","unstructured":"Venzi M, David F, Bellet J, Cavaccini A, Bombardi C, Crunelli V, et al. Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures. Neuropharmacology. 2016;108:292\u2013304. \n                      https:\/\/doi.org\/10.1016\/j.neuropharm.2016.04.016\n                      \n                    .","journal-title":"Neuropharmacology"},{"issue":"4","key":"537_CR67","doi-asserted-by":"publisher","first-page":"ENEURO.0066-17.","DOI":"10.1523\/ENEURO.0066-17.2017","volume":"4","author":"Brian P. Grone","year":"2017","unstructured":"Grone BP, Qu T, Baraban SC. Behavioral comorbidities and drug treatments in a zebrafish scn1lab model of Dravet syndrome. Eneuro. 2017;4. \n                      https:\/\/doi.org\/10.1523\/ENEURO.0066-17.2017\n                      \n                    .","journal-title":"eneuro"},{"key":"537_CR68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature05756","volume":"447","author":"EM Welch","year":"2007","unstructured":"Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87\u201391. \n                      https:\/\/doi.org\/10.1038\/nature05756\n                      \n                    .","journal-title":"Nature"},{"key":"537_CR69","doi-asserted-by":"publisher","first-page":"12353","DOI":"10.1073\/pnas.1615548113","volume":"113","author":"N Siddiqui","year":"2016","unstructured":"Siddiqui N, Sonenberg N. Proposing a mechanism of action for ataluren. Proc Natl Acad Sci. 2016;113:12353\u20135. \n                      https:\/\/doi.org\/10.1073\/pnas.1615548113\n                      \n                    .","journal-title":"Proc Natl Acad Sci"},{"key":"537_CR70","doi-asserted-by":"publisher","unstructured":"Kosmidis G, Veerman CC, Casini S, Verkerk AO, Van De Pas S, Bellin M, et al. Readthrough-promoting drugs gentamicin and PTC124 fail to rescue Na v 1.5 function of human-induced pluripotent stem cell-derived cardiomyocytes carrying nonsense mutations in the sodium channel gene SCN5A. Circ Arrhythmia Electrophysiol. 2016;9. \n                      https:\/\/doi.org\/10.1161\/CIRCEP.116.004227\n                      \n                    .","DOI":"10.1161\/CIRCEP.116.004227"},{"key":"537_CR71","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.pediatrneurol.2003.10.012","volume":"30","author":"BPGM Ceulemans","year":"2004","unstructured":"Ceulemans BPGM, Claes LRF, Lagae LG. Clinical correlations of mutations in the SCN1A gene: from febrile seizures to severe myoclonic epilepsy in infancy. Pediatr Neurol. 2004;30:236\u201343. \n                      https:\/\/doi.org\/10.1016\/j.pediatrneurol.2003.10.012\n                      \n                    .","journal-title":"Pediatr Neurol"},{"key":"537_CR72","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1086\/320609","volume":"68","author":"L Claes","year":"2001","unstructured":"Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68:1327\u201332. \n                      https:\/\/doi.org\/10.1086\/320609\n                      \n                    .","journal-title":"Am J Hum Genet"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-018-0537-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-018-0537-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-018-0537-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T22:07:59Z","timestamp":1570918079000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-018-0537-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,13]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["537"],"URL":"https:\/\/doi.org\/10.1007\/s11940-018-0537-y","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,13]]},"assertion":[{"value":"13 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Kelly G. Knupp reports grants from Zogenix Inc., grants from West Therapeutics, grants from Pediatric epilepsy research fund, personal fees from Stoke therapeutics, and grants from Colorado Department of Public Health, outside the submitted work. Joseph E. Sullivan reports grants from Zogenix, personal fees from Epygenix, and personal fees from Miller Medical, outside the submitted work; and Medical Advisory Board-Dravet Syndrome Foundation. Julie Ziobro and Krista Eschbach each declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"52"}}